Eine randomisierte, kontrollierte Behandlungsstudie beim Reizdarmsyndrom mit einer probiotischen E.-coli-Praparation (DSM17252) im Vergleich zu Placebo

摘要

Background: Therapy trials with bacterial compounds in irritable bowel syndrome (IBS) have produced conflicting results and, so far, an E.-coli preparation has not been used.Methods: Two hundred and ninety-eight patients with lower abdominal symptoms diagnosed as IBS were treated for 8 weeks by the compound Symbioflor~R-2 (Symbiopharm GmbH, Herborn, Germany), an Escherichia coli product (N = 148), or placebo (n = 150) in a double-blinded, randomized fashion. Patients were seen weekly by the physician, who assessed the presence of core IBS symptoms. Both an abdominal pain score (APS) as well as a general symptom score (GSS) were used as primary endpoints. Re-sponders had to have complete absence of IBS core symptoms at > 1 visit during treatment.